Nocion Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nocion Therapeutics, Inc. - overview
Established
2017
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and Founded in 2017 by co-founders Bruce Levy MD, Clifford Woolf Ph. D, and Bruce Bean Ph. D, Nocion Therapeutics, Inc. operates as a provider of various therapies for neurogenic inflammation conditions, offering solutions to patients with pain, cough, itch, and inflammation.
In February 2024, Nocion Therapeutics, Inc. raised USD 31. 11 million in series B funding co-led by Arkin Holdings and Monograph Capital Partners, with participation Canaan Partners, F-Prime Capital, Mass General Brigham Ventures, Mission BioCapital, and OUP (Osage University Partners. As of 2024, the company is led by its CEO, Richard Batycky Ph.
D. The company provides a wide range of biopharmaceutical products, such as nocions, which selectively affect activated sensory neurons to treat conditions like chronic cough, pain, itch, and inflammation. Nocions block sodium channels in inflamed nociceptors, providing long-acting relief. Additionally, the firm also provides therapies targeting various indications in pulmonology, gynecology, urology, dermatology, gastroenterology, and ophthalmology.
Current Investors
Canaan Partners, F-Prime Capital, Mass General Brigham Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.nociontx.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.